Enanta Pharmaceuticals (NASDAQ:ENTA) Coverage Initiated at Rodman & Renshaw

Stock analysts at Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a “buy” rating and a $20.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s price objective points to a potential upside of 64.20% from the stock’s previous close.

Several other research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Wednesday, January 21st. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $12.18 on Thursday. The stock’s 50 day moving average price is $13.42 and its 200 day moving average price is $12.61. The firm has a market capitalization of $353.46 million, a PE ratio of -3.81 and a beta of 0.96. Enanta Pharmaceuticals has a one year low of $4.09 and a one year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.12. The company had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. On average, analysts forecast that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Janus Henderson Group PLC boosted its stake in Enanta Pharmaceuticals by 91.6% in the fourth quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock valued at $58,761,000 after acquiring an additional 1,782,745 shares during the period. Farallon Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 30.6% during the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after purchasing an additional 650,000 shares during the period. Krensavage Asset Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after purchasing an additional 449,945 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Enanta Pharmaceuticals by 0.8% during the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after purchasing an additional 6,522 shares during the period. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.